Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine liposomal
- Development stage
- Unknown
- Lead developer
- BC Cancer
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
**hydroxychloroquine liposomal** (also known as TLC19 or ISPM19) is an inhalable liposomal formulation of the antimalarial and immunomodulatory drug hydroxychloroquine. Developed by Taiwan Liposome Company (TLC) and its subsidiary InspirMed, it is designed to deliver hydroxychloroquine directly to the respiratory tract and lungs via inhalation. This targeted delivery achieves high therapeutic concentrations in the lungs while minimizing systemic exposure, thereby reducing the risk of dose-limiting toxicities such as cardiotoxicity. It has been investigated in Phase I clinical trials for the treatment and prophylaxis of COVID-19. Additionally, academic researchers (including the BC Cancer Agency and the University of British Columbia) have explored liposomal hydroxychloroquine formulations for other indications, such as inhibiting cytoprotective autophagy in breast cancer (in combination with autophagy-inducing drugs like gefitinib) and treating acute lung injury.
- Other names
- HCQ-Lhydroxychloroquine liposome inhalation suspensioninhalable liposomal hydroxychloroquineL-HCQliposomal hydroxychloroquine
02
Targets
PPT1 (Palmitoyl-protein thioesterase 1)TLR9 (Toll-like receptor 9)DNA
Beyond the preview
Go deeper on hydroxychloroquine liposomal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine liposomal.